The Data Safety Monitoring Board (DSMB) for VIA Pharmaceuticals’ VIA-2291 Phase 2 clinical trial program has met to review patient safety for the current Phase 2 studies.
The DSMB has observed a continued acceptable safety profile of VIA-2291 and has allowed VIA to continue its ongoing trials as planned, the San Francisco-based VIA said.
“We are encouraged by the continued positive safety profile of VIA-2291 as we enroll more patients in our Phase 2 clinical program,” said Adeoye Olukotun, MD, chief medical officer for VIA. “We believe that a drug that reduces inflammation, an underlying cause of atherosclerosis and complications including heart attack and stroke, would help to address a significant unmet medical need.”
VIA has completed the enrollment for its Phase 2 carotid endarterectomy trial and expects to present results in the third quarter of 2008.